Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphoma

This study has been completed.
Information provided by (Responsible Party):
Shams Shakil, University of Kentucky Identifier:
First received: May 11, 2009
Last updated: October 13, 2016
Last verified: October 2016
This is a phase I, prospective, open label, dose escalation study of azacitidine in combination with rituximab, vincristine, and cyclophosphamide for the treatment of refractory lymphoma. The investigators expect to enroll 12-24 patients in this trial over a 2 year accrual period.

Condition Intervention Phase
Hodgkin Disease
Lymphoma, Non-Hodgkin
Drug: Azacitidine with rituximab, vincristine, and cyclophosphamide
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphoma: A Phase I Trial

Resource links provided by NLM:

Further study details as provided by University of Kentucky:

Primary Outcome Measures:
  • Determine the maximal tolerated dose (MTD) of azacitidine in combination with rituximab, vincristine, and cyclophosphamide in patients with lymphoma [ Time Frame: Eight 21 day cycles ] [ Designated as safety issue: Yes ]

Enrollment: 12
Study Start Date: May 2009
Study Completion Date: November 2012
Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Azacitidine Drug: Azacitidine with rituximab, vincristine, and cyclophosphamide
Azacitidine cycle days 1-5 Cyclophosphamide cycle days 6-9 Vincristine cycle day 8 Rituximab cycle day 8 Rituximab is only for those patients with CD20+ lymphoma. Azacitidine 25 mg/m2^ Azacitidine 50 mg/m2^ Azacitidine 75 mg/m2^ Azacitidine 100 mg/m2^


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patient or their authorized legally acceptable representative must consent to be in the study and must have signed and dated an approved consent form which conforms to federal and institutional guidelines.
  2. Age ≥ 18 years and without a maximum age.
  3. All patients of reproductive potential should not plan on conceiving children during the treatment program and must agree to use a medically accepted form of contraception.
  4. Women of childbearing potential must have a negative serum pregnancy test within 2 weeks of beginning treatment.
  5. Patients must have relapsed lymphoma.
  6. ECOG performance status of 2 or better.

Exclusion Criteria:

  1. Pregnant or breast-feeding at the time of proposed study entry
  2. Clinical AIDS or ARS or known positive HIV serology
  3. History of malignant neoplasm, other than lymphoma, treated within two years prior to study entry (other than non-melanoma skin cancer or in situ cervical cancer) or where there is current evidence of recurrent or metastatic disease
  4. Psychiatric or additive disorders that would preclude obtaining informed consent
  5. Serum bilirubin > 1.5 times the upper limit of the normal range for the laboratory (ULN). Higher levels are acceptable if these are attributed to active hemolysis
  6. Serum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) or serum glutamic-pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) levels > 2 times ULN
  7. Serum creatinine levels > 1.5 times ULN
  8. Platelets < 75,000/mm3
  9. Absolute neutrophil count < 1500/mm3
  10. Active infection including viral hepatitis
  11. Known or suspected hypersensitivity to mannitol, azacitidine, or rituximab
  12. Grade 3 or 4 neuropathy
  13. Advanced hepatic tumors
  14. Uncompensated heart failure
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00901069

United States, Kentucky
University of Kentucky
Lexington, Kentucky, United States, 40536
Sponsors and Collaborators
Shams Shakil
Principal Investigator: Shams Shakil, MD Lucille P. Markey Cancer Center at University of Kentucky
  More Information

Responsible Party: Shams Shakil, Principal Investigator, University of Kentucky Identifier: NCT00901069     History of Changes
Obsolete Identifiers: NCT00589160
Other Study ID Numbers: 07-NHL-06-UK/CC 
Study First Received: May 11, 2009
Last Updated: October 13, 2016
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Hodgkin Disease
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Antineoplastic Agents, Phytogenic
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Antimetabolites, Antineoplastic
Enzyme Inhibitors processed this record on October 21, 2016